Australian Government Accused of Misusing Funds to Combat E-Cigarettes

Sep.09.2022
Australian Government Accused of Misusing Funds to Combat E-Cigarettes
CAPHRA Coordinator Nancy Loucas criticizes Australian government's anti-vaping campaign as a misuse of public funds.

Nancy Loucas, the executive coordinator of the Asia Pacific Advocates for Tobacco Harm Reduction (CAPHRA), has expressed that the crackdown on e-cigarette retailers in Australia constitutes a serious misuse of public funds, which should be directed towards improving the country's healthcare system.


Before she issued her statement, the government of New South Wales in Australia intensified its warnings to compliant retailers about the risks associated with e-cigarette products. They also continue to back a controversial joint "education campaign" with the Department of Education on the issue of e-cigarettes.


The centerpiece of the event is the "Get the Facts" - Vaping Toolkit aimed at teachers, parents, and adolescent students. CAPHRA stated that despite Deputy Chief Health Officer Dr. Marianne Gale's assurance that the website does not contain "evidence-based resources and educational materials," it should be taken down while its many statements are independently verified.


These claims about electronic cigarettes are either completely exaggerated or, in the worst case scenario, have no scientific basis. The Australian public, regardless of age, needs to have complete confidence in any health statements on government websites. Unfortunately, this campaign is far from factual. Instead, it is filled with blatant lies," said Ms. Lucas.


In a statement that has angered advocates for tobacco harm reduction (THR) throughout the entire Asia-Pacific region, Dr. Gale claimed, "Many people believe that e-cigarettes are either completely harmless or less harmful than traditional cigarettes.


In a recent situation, an Australian chief health officer has been actively informing the public that the harm of vaping is not less than smoking. However, international research strongly refutes this claim. Despite providing no evidence to support her statement, the Australian public continues to receive such costly yet worthless advice. This is a complete embarrassment," she said.


According to CAPHRA, Australians who want to know the truth about vaping should look to New Zealand. Adults can legally use nicotine e-cigarettes there under regulations targeting retailers and manufacturers in 2020. Smokers looking to quit do not need to obtain a prescription from a doctor, unlike in Australia.


Asking doctors to prescribe cigarettes has left 2.3 million smokers in Australia disappointed, not to mention the approximately 20,000 Australians who die each year from smoking-related illnesses. While Australia's overall smoking rate has remained stagnant over the past decade, New Zealand has seen a 50% decrease in its smoking rate, largely due to the availability of legally sanctioned, less harmful alternatives for smokers, according to Ms. Lucas.


CAPHRA has pointed out that the headline of the New Zealand Ministry of Health's "Vaping facts" website states that "vaping is less harmful than smoking".


New Zealand is engaging in a positive dialogue with the public with the goal of achieving a smoke-free nation by 2025, with a smoking rate of 5% or less. In contrast, health leaders in Australia are continuing to ban adults from entering retail stores while using significant public resources to deter the use of e-cigarettes.


Australia's healthcare system is failing miserably. The persistent threats and lies surrounding e-cigarettes will make it almost impossible to achieve the country's goal of reducing smoking rates by 10% in the short term. They need a new strategy to eradicate tobacco, as the current one clearly isn't working," said Nancy Lucas.


CAPHRA, an advocacy group, has amassed almost 15,000 endorsement letters and is urging those who have quit smoking through the use of nicotine-free alternatives to share their stories on www.righttovape.org.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the opinion of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article’s content. The compilation of this article is only intended for industry exchange and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
South Korea Vape Strategies Diverge as BAT Reconsiders Exit and PMI Takes VEEV to About 14,000 Stores
BAT Rothmans says it previously considered exiting South Korea's vaping market because of competitive pressure from unregulated products, but is now reassessing conditions following changes to the country's nicotine regulatory framework. Vuse and other BAT vaping products remain available through existing distribution channels. The statement followed a South Korean media report that interpreted BAT's broader withdrawal from selected Vapour markets as a full exit from South Korea. Meanwhile, Philip Morris International launched VEEV inPRIME in the country in June and began expanding distribution to around 14,000 convenience stores and other retail channels in July. The contrasting moves highlight differing investment strategies as South Korea's regulated vaping market evolves.
Aug.14
PMI Expands IQOS and VEEV Presence at Frankfurt Airport Through Travel Retail Pop-Ups
PMI Expands IQOS and VEEV Presence at Frankfurt Airport Through Travel Retail Pop-Ups
According to The Moodie Davitt Report, PMI Global Travel Retail and Frankfurt Airport Retail have launched new IQOS and VEEV retail spaces at Frankfurt Airport. The installations, located inside and outside duty-free areas, showcase IQOS heated tobacco products and VEEV e-vapor products through product education, consumer interaction and brand experiences. Frankfurt Airport Retail, operated by Fraport Group and Gebr. Heinemann, manages key retail activities at Frankfurt Airport. The initiative follows PMI’s broader strategy of expanding smoke-free products through global travel retail channels. PMI has previously introduced VEEV products across multiple European airports while continuing to expand IQOS and VEEV availability in international markets.
Jul.17
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
Japan Health Ministry Cites Limited Evidence in Decision Not to Tighten Heated Tobacco Rules
Japan Health Ministry Cites Limited Evidence in Decision Not to Tighten Heated Tobacco Rules
Japan’s health ministry has proposed not tightening regulations on heated tobacco products to the same level as cigarettes as part of a review of passive smoking measures, with an expert panel broadly agreeing with the proposal, Jiji Press reported.
Jul.10
Product | Republic Technologies Launches ZIG Nicotine Pouches, Expanding Beyond Traditional Tobacco Accessories
Product | Republic Technologies Launches ZIG Nicotine Pouches, Expanding Beyond Traditional Tobacco Accessories
Republic Technologies UK has entered the nicotine pouch market with ZIG Nicotine Pouches, marking the company’s expansion beyond traditional tobacco-related accessories into smoke-free nicotine products. The product is expected to enter UK retail channels from August 2026, including convenience stores, supermarkets and tobacco retailers. The launch includes six flavors and three nicotine strengths: 8mg, 12mg and 17mg.
Market
Jul.21 by 2Firsts Perspectives